These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21537560)

  • 1. Imipramine for vestibular dysfunction in panic disorder: a prospective case series.
    Mezzasalma MA; Mathias Kde V; Nascimento I; Valença AM; Nardi AE
    Arq Neuropsiquiatr; 2011 Apr; 69(2A):196-201. PubMed ID: 21537560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic dizziness presenting in a patient with panic disorder: response to imipramine.
    Mezzasalma MA; Mathias Kde V; Nascimento I; Valença AM; Nardi AE
    Arq Neuropsiquiatr; 2009 Mar; 67(1):121-2. PubMed ID: 19330229
    [No Abstract]   [Full Text] [Related]  

  • 3. Imipramine on the treatment of chronic dizziness and panic disorder--3 cases report.
    Mezzasalma MA; Mathias Kde V; Nascimento I; Valença AM; Nardi AE
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 May; 34(4):717-8. PubMed ID: 20307620
    [No Abstract]   [Full Text] [Related]  

  • 4. The use of the Panic and Agoraphobia Scale in a clinical trial.
    Bandelow B; Brunner E; Broocks A; Beinroth D; Hajak G; Pralle L; Rüther E
    Psychiatry Res; 1998 Jan; 77(1):43-9. PubMed ID: 10710174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia.
    Mavissakalian MR; Perel JM
    Arch Gen Psychiatry; 1999 Sep; 56(9):821-7. PubMed ID: 12884888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia.
    Mavissakalian MR; Perel JM; Talbott-Green M; Sloan C
    Biol Psychiatry; 1998 Jun; 43(11):848-54. PubMed ID: 9611676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of a new statistical approach to evaluate a clinical trial with panic disorder patients.
    Bandelow B; Brunner E; Beinroth D; Pralle L; Broocks A; Hajak G; Rüther E
    Eur Arch Psychiatry Clin Neurosci; 1999; 249(1):21-7. PubMed ID: 10195340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The side effects burden of extended imipramine treatment of panic disorder.
    Mavissakalian MR; Perel JM
    J Clin Psychopharmacol; 2000 Oct; 20(5):547-55. PubMed ID: 11001240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2nd year maintenance and discontinuation of imipramine in panic disorder with agoraphobia.
    Mavissakalian MR; Perel JM
    Ann Clin Psychiatry; 2001 Jun; 13(2):63-7. PubMed ID: 11534926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of outcome in panic disorder: a 5-year prospective follow-up study.
    Scheibe G; Albus M
    J Affect Disord; 1996 Nov; 41(2):111-6. PubMed ID: 8961038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial.
    Barlow DH; Gorman JM; Shear MK; Woods SW
    JAMA; 2000 May; 283(19):2529-36. PubMed ID: 10815116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder.
    Lepola U; Arató M; Zhu Y; Austin C
    J Clin Psychiatry; 2003 Jun; 64(6):654-62. PubMed ID: 12823079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adrenergic receptor function in panic disorder. I. Platelet alpha 2 receptors: Gi protein coupling, effects of imipramine, and relationship to treatment outcome.
    Gurguis GN; Antai-Otong D; Vo SP; Blakeley JE; Orsulak PJ; Petty F; Rush AJ
    Neuropsychopharmacology; 1999 Feb; 20(2):162-76. PubMed ID: 9885796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia.
    Bakish D; Hooper CL; Filteau MJ; Charbonneau Y; Fraser G; West DL; Thibaudeau C; Raine D
    Psychopharmacol Bull; 1996; 32(1):135-41. PubMed ID: 8927663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imipramine treatment of panic disorder with agoraphobia: the second time around.
    Mavissakalian MR; Perel JM; de Groot C
    J Psychiatr Res; 1993; 27(1):61-8. PubMed ID: 8515390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure.
    Cox BJ; Endler NS; Lee PS; Swinson RP
    J Behav Ther Exp Psychiatry; 1992 Sep; 23(3):175-82. PubMed ID: 1487535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships.
    Mavissakalian MR; Perel JM
    Am J Psychiatry; 1995 May; 152(5):673-82. PubMed ID: 7726306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo.
    Sheikh JI; Swales PJ
    Int J Psychiatry Med; 1999; 29(1):107-17. PubMed ID: 10376237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo.
    Marchand A; Coutu MF; Dupuis G; Fleet R; Borgeat F; Todorov C; Mainguy N
    Cogn Behav Ther; 2008; 37(3):146-59. PubMed ID: 18608313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minnesota Multiphasic Personality Inventory correlates of panic disorder with agoraphobia: changes with treatment.
    Ito LM; Gorenstein C; Gentil V; Miyakawa E
    Braz J Med Biol Res; 1995 Sep; 28(9):961-5. PubMed ID: 8580883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.